Crohn's Disease News and Research

Latest Crohn's Disease News and Research

RA patients who adhere to their prescription drug regimen have better outcome: Study

Rheumatoid arthritis (RA) patients who regularly adhere to their prescription drug regimen have fewer emergency room and doctor visits and incur lower medical costs, according to research presented today by Medco Health Solutions, Inc. at the American College of Rheumatology's Annual Meeting in Philadelphia.

20 Oct 2009

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

19 Oct 2009

Discovery may yield better understanding of protective gut-dwelling bacteria

Medical researchers have long suspected that obscure bacteria living within the intestinal tract may help keep the human immune system in balance. An international collaboration co-led by scientists at NYU Langone Medical Center has now identified a bizarre-looking microbial species that can single-handedly spur the production of specialized immune cells in mice.

19 Oct 2009

Research programme to develop immunological biomarkers for chronic inflammatory diseases

Persistent inflammation and the activation of the immune system is the key pathological mechanism affecting many long-term conditions, such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease and is the predominant mechanism underlying organ transplant rejection.

19 Oct 2009

Enzo Biochem to release a new catalog dealing with epigenetics and chromatin modification

Enzo Biochem, Inc. today said that its Life Sciences subsidiary will release a new catalog dealing with “Epigenetics & Chromatin Modification” at the Society for Neuroscience’s, Neuroscience 2009 conference, beginning October 17, 2009, in Chicago, Illinois.

15 Oct 2009

National Vaccine Information Center to launch a research fundraising campaign

At the Oct. 2-4, 2009 Fourth International Public Conference on Vaccination sponsored by the non-profit National Vaccine Information Center in Reston, VA, 700 citizens from 44 states and 11 nations raised more than $100,000 to launch an international scientific research fundraising campaign to investigate health differences between vaccinated and unvaccinated children and identify those at risk for suffering vaccine injury.

14 Oct 2009

Sequella receives Phase 1 SBIR grant for developing SQ641

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.

13 Oct 2009

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.

12 Oct 2009

Destructive immune cells gain access to insulin-producing cells and help cause diabetes

St. Jude Children's Research Hospital investigators have discovered how destructive immune cells gain access to insulin-producing cells and help cause diabetes.

9 Oct 2009

New findings on genetic disorder may lead to better treatment of inflammatory bowel disease

New findings related to an uncommon genetic disorder may impact the diagnosis and treatment of inflammatory bowel disease (IBD), the most common chronic gastrointestinal illness in children and teens.

9 Oct 2009

Pfizer-FRSQ Innovation Fund supports genetic study of inflammatory bowel disease and cancer

The first two research projects supported by the Pfizer-FRSQ Innovation Fund will investigate differences in the genetic code for inflammatory bowel disease and metastatic colorectal cancer. This research could lead to improved diagnosis and the development of individualized treatments for these diseases. These innovative projects are marshalling multidisciplinary teams of seasoned researchers from major Quebec research institutions.

8 Oct 2009

New apoptosis detection kit for monitoring chromatin condensation

Enzo Biochem, Inc.’s Enzo Life Sciences division today announced the addition of a new apoptosis detection kit for monitoring chromatin condensation to its rapidly expanding CELLestial™ product line for live cell analysis.

7 Oct 2009

Shire publishes efficacy study results of FOSRENOL and Renagel

Shire plc, the global specialty biopharmaceutical company, today announces the publication in Clinical Nephrology of findings from a head-to-head clinical study comparing the efficacy of two non-calcium based phosphate binders, FOSRENOL(R) (lanthanum carbonate) and sevelamer hydrochloride (Genzyme's Renagel(R)) in chronic kidney disease (CKD) patients on haemodialysis.

7 Oct 2009

16 Canadian students living with chronic illness to receive UCBeyond Scholarships

What would you do if you were faced with a chronic illness? Would you walk across Canada to raise awareness for Crohn's disease, build houses in developing countries despite physical pain or dedicate your career to educating young people living with the same disease as you?

6 Oct 2009

TNF-alpha inhibitor drug class sales to increase up to $1.1 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to sales of Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma's Remicade, the two emerging TNF-alpha inhibitors Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma/Janssen's Simponi will drive sales of the TNF-alpha inhibitor drug class to nearly triple by 2018 for the treatment of ulcerative colitis.

3 Oct 2009

Co-marketing partnership between Enzo Life Sciences and BioTek Instruments

Enzo Biochem, Inc. announced today a co-marketing partnership between its Enzo Life Sciences subsidiary, a world leader in non-radioactive probe technology, and BioTek Instruments, a privately held global leader in the development, manufacture and sale of microplate instrumentation for drug discovery and life science applications, involving powerful, integrated solutions for high throughput live cell analysis.

3 Oct 2009

Mayo study reveals infliximab reduces the need for colectomy

A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology.

1 Oct 2009

Meridian Bioscience Europe to distribute the BÜHLMANN Calprotectin test in Italy

Meridian Bioscience, Inc., Cincinnati, Ohio announced today that Meridian Bioscience Europe srl, Milan, Italy has signed an agreement with BÜHLMANN Laboratories AG, Schönenbuch, Switzerland for distribution in Italy of an innovative test for inflammatory conditions of the intestine, Quantum Blue® Calprotectin.

1 Oct 2009

La Jolla Institute scientist Hilde Cheroutre earns the 2009 NIH Director's Pioneer Award

A scientist at the La Jolla Institute for Allergy & Immunology has received one of the National Institutes of Health (NIH)'s top awards -- the 2009 NIH Director's Pioneer Award. The prestigious prize carries with it funding for total costs of up to $4.7 million over five years, and is designed to support the work of exceptionally creative scientists, whose novel proposals offer the potential to make extraordinary contributions to human health.

24 Sep 2009

Collaborative clinical care network at Cincinnati Children's Hospital Medical Center

Fostering innovation to speed the improvement of health care is the goal of an $8.3 million grant to researchers at Cincinnati Children's Hospital Medical Center.

24 Sep 2009

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

RA patients who adhere to their prescription drug regimen have better outcome: Study

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

Discovery may yield better understanding of protective gut-dwelling bacteria

Research programme to develop immunological biomarkers for chronic inflammatory diseases

Enzo Biochem to release a new catalog dealing with epigenetics and chromatin modification

National Vaccine Information Center to launch a research fundraising campaign

Sequella receives Phase 1 SBIR grant for developing SQ641

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Destructive immune cells gain access to insulin-producing cells and help cause diabetes

New findings on genetic disorder may lead to better treatment of inflammatory bowel disease

Pfizer-FRSQ Innovation Fund supports genetic study of inflammatory bowel disease and cancer

New apoptosis detection kit for monitoring chromatin condensation

Shire publishes efficacy study results of FOSRENOL and Renagel

16 Canadian students living with chronic illness to receive UCBeyond Scholarships

TNF-alpha inhibitor drug class sales to increase up to $1.1 billion in 2018

Co-marketing partnership between Enzo Life Sciences and BioTek Instruments

Mayo study reveals infliximab reduces the need for colectomy

Meridian Bioscience Europe to distribute the BÜHLMANN Calprotectin test in Italy

La Jolla Institute scientist Hilde Cheroutre earns the 2009 NIH Director's Pioneer Award

Collaborative clinical care network at Cincinnati Children's Hospital Medical Center

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in